Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.
Giant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutio...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797105408601489408 |
|---|---|
| author | Direskeneli, H Aydin, S Kermani, T Matteson, E Boers, M Herlyn, K Luqmani, R Neogi, T Seo, P Suppiah, R Tomasson, G Merkel, P |
| author_facet | Direskeneli, H Aydin, S Kermani, T Matteson, E Boers, M Herlyn, K Luqmani, R Neogi, T Seo, P Suppiah, R Tomasson, G Merkel, P |
| author_sort | Direskeneli, H |
| collection | OXFORD |
| description | Giant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development. |
| first_indexed | 2024-03-07T06:47:07Z |
| format | Journal article |
| id | oxford-uuid:fb3f5e77-fb0b-416c-a797-c1ee7eea7df3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:47:07Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:fb3f5e77-fb0b-416c-a797-c1ee7eea7df32022-03-27T13:12:16ZDevelopment of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fb3f5e77-fb0b-416c-a797-c1ee7eea7df3EnglishSymplectic Elements at Oxford2011Direskeneli, HAydin, SKermani, TMatteson, EBoers, MHerlyn, KLuqmani, RNeogi, TSeo, PSuppiah, RTomasson, GMerkel, PGiant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development. |
| spellingShingle | Direskeneli, H Aydin, S Kermani, T Matteson, E Boers, M Herlyn, K Luqmani, R Neogi, T Seo, P Suppiah, R Tomasson, G Merkel, P Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. |
| title | Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. |
| title_full | Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. |
| title_fullStr | Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. |
| title_full_unstemmed | Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. |
| title_short | Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. |
| title_sort | development of outcome measures for large vessel vasculitis for use in clinical trials opportunities challenges and research agenda |
| work_keys_str_mv | AT direskenelih developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT aydins developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT kermanit developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT mattesone developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT boersm developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT herlynk developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT luqmanir developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT neogit developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT seop developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT suppiahr developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT tomassong developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda AT merkelp developmentofoutcomemeasuresforlargevesselvasculitisforuseinclinicaltrialsopportunitieschallengesandresearchagenda |